Close Menu

Breaking News

Based on PCR technology acquired from Hain Diagnostics, the test and platform enable rapid detection of TB, as well as assessment of antibiotic resistance.

With single-cell genome sequencing, recombination assays, and other approaches in mouse cells, researchers identified factors affecting DNA crossover.

The study adds to growing evidence around the utility of cell-free DNA testing in lung cancer patients, while highlighting shortcomings of the approach.

Sequencing analysis of the Enterococcus faecium isolates found that they belonged to two clades, one of which harbored numerous resistance genes.

Molecular features in primary and recurrent glioblastomas indicated that key initiator mutations turned up years before diagnosis, often persisting in recurrent tumors.

The Navify software, which Roche launched today, provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer.

The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.

Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.

The test detects Group A Strep in throat swab samples using the firm's rapid molecular diagnostics instrument called Revogene.

The companies will use their respective technologies in a study investigating the associations between ovarian cancer and the gut microbiome.

Researchers designed a PCR-based test for pyrethroid resistance based on a cytochrome P450 allele that is common in Anopheles funestus mosquitoes from Malawi.

Researchers reported finding oncohistone mutations within nearly 4 percent of tumors and said they could alter the structure and function of chromatin.

With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.

With ancient mitochondrial sequences from all seven Canary Islands, researchers identified at least two early migrations involving shifting populations from North Africa.

The company said it will offer 4.5 million shares for $23 per share and intends to use the net proceeds for working capital and general corporate purposes.

For full-year 2018 the firm's revenues rose 38 percent to $21.9 million from $15.9 million a year ago.

In addition, a German court found in December that German NIPT company Cenata infringes Streck's patent.

The researchers found evidence of genetic continuity in Anatolia, even as the subsistence strategy changed from hunting and gathering to farming.

The test will be designed to detect a protein biomarker in aqueous humor that can be used to determine the severity of glaucoma and to make treatment decisions.

The company said it will offer 2.5 million shares, while stockholder Clarus Lifesciences will sell another 2 million shares in the offering.

Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.

The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.

The companies will initially work on a shotgun metagenomic sequencing-based service for microbiome research that will be offered internationally.

The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.

Pages

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.